Aurinia Pharmaceuticals AUPH U.S. — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aurinia Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's u.s. — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's U.S. — revenue?
- Aurinia Pharmaceuticals (AUPH) reported U.S. — revenue of $65.96M in Q4 2025.
- How has Aurinia Pharmaceuticals's U.S. — revenue changed year-over-year?
- Aurinia Pharmaceuticals's U.S. — revenue increased by 25.6% year-over-year, from $52.52M to $65.96M.
- What is the long-term trend for Aurinia Pharmaceuticals's U.S. — revenue?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's U.S. — revenue has grown at a 55.2% compound annual growth rate (CAGR), from $45.49M to $263.84M.
- What does U.S. — revenue mean?
- This metric represents the total gross sales generated from pharmaceutical products and services within the United States geographic market. It serves as a primary indicator of commercial adoption and market penetration for the company's therapeutic portfolio in its largest operating region. Growth in this figure reflects successful sales execution and increasing patient access to the company's treatments.